Cholinesterase inhibitors, commonly prescribed for Alzheimer's disease, are not recommended for mild neurocognitive disorders due to a lack of demonstrated efficacy [6-7]. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.